Zealand Pharma has entered a deal worth up to $1.2 billion with Generate Biomedicines to develop AI-designed multispecific protein treatments for obesity. Generate receives $30 million upfront and $35 million in early milestones to lead research across initial programs, while Zealand handles clinical development and commercialization. The deal expands Zealand's obesity pipeline alongside its $5.3 billion Roche partnership for petrelintide.
Scope and responsibilities of the partnership
- ▪The $1.2 billion development agreement between Zealand Pharma and Generate Biomedicines initially covers two experimental drug programs, with an option to add a third program
- ▪Under their $1.2 billion obesity drug deal, Generate Biomedicines will lead research through candidate selection, while Zealand Pharma will handle clinical development, regulatory submissions, and worldwide commercialization
- ▪Danish developer Zealand Pharma partnered with US biotechnology company Generate Biomedicines to develop AI-based protein treatments for obesity and metabolic diseases in a deal worth up to $1.2 billion
Multispecific protein therapy approach
- ▪The collaboration between Zealand Pharma and Generate Biomedicines focuses on multispecific protein therapies engineered to act on more than one biological target at a time
- ▪Multispecific protein treatments allow drugmakers to target several distinct disease pathways linked to obesity within a single therapeutic medicine
Generate Biomedicines stock history
- ▪Following the Zealand Pharma-Generate Biomedicines partnership announcement on October 13, 2026, shares of Generate Biomedicines rose approximately 5% in extended trading
- ▪Generate Biomedicines held its initial public offering at the Nasdaq MarketSite in New York City on February 27, 2026
Obesity treatment market trends
- ▪The commercial success of GLP-1 weight-loss drugs has fueled increased investment across the broader obesity treatment market
- ▪Drugmakers are seeking next-generation obesity treatments beyond GLP-1 weight-loss drugs sold by Novo Nordisk and Eli Lilly to improve effectiveness, convenience, and side-effect profiles
Zealand Pharma's petrelintide development
- ▪Zealand Pharma is jointly developing the obesity drug petrelintide with Roche under a 2025 agreement worth up to $5.3 billion
- ▪In October 2026, Zealand Pharma reported mid-stage trial results showing petrelintide helped overweight and obese patients with type 2 diabetes lose up to 9.2% of their body weight
Debatable claims
- ▪Multispecific protein therapies offer a superior treatment model for obesity than single-target GLP-1 drugs
- ▪AI-driven protein design offers a viable pathway for discovering metabolic disease treatments
Story comments
Loading comments…